These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 23970584)

  • 1. Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety.
    Perry ME; Almaani N; Desai N; Larbalestier N; Fox J; Chilton D
    Int J STD AIDS; 2013 Aug; 24(8):639-42. PubMed ID: 23970584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raltegravir-induced DRESS syndrome.
    Loulergue P; Mir O
    Scand J Infect Dis; 2012 Oct; 44(10):802-3. PubMed ID: 22803794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dolutegravir as a trigger for DRESS syndrome?
    Martin C; Payen MC; De Wit S
    Int J STD AIDS; 2018 Sep; 29(10):1036-1038. PubMed ID: 29621952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DRESS syndrome associated with raltegravir.
    Zhang KS; Modi GM; Hsu S
    Dermatol Online J; 2011 Aug; 17(8):14. PubMed ID: 21906494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extensive pulmonary involvement with raltegravir-induced DRESS syndrome in a postpartum woman with HIV.
    Yee BE; Nguyen NH; Lee D
    BMJ Case Rep; 2014 May; 2014():. PubMed ID: 24798353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
    Martínez E; Larrousse M; Llibre JM; Gutiérrez F; Saumoy M; Antela A; Knobel H; Murillas J; Berenguer J; Pich J; Pérez I; Gatell JM;
    AIDS; 2010 Jul; 24(11):1697-707. PubMed ID: 20467288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The DRESS syndrome: the great clinical mimicker.
    Fleming P; Marik PE
    Pharmacotherapy; 2011 Mar; 31(3):332. PubMed ID: 21361742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenytoin-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a case report from the emergency department.
    Oelze LL; Pillow MT
    J Emerg Med; 2013 Jan; 44(1):75-8. PubMed ID: 21852061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raltegravir, an HIV-1 integrase inhibitor for HIV infection.
    Cabrera C
    Curr Opin Investig Drugs; 2008 Aug; 9(8):885-98. PubMed ID: 18666037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First report of lamotrigine-induced drug rash with eosinophilia and systemic symptoms syndrome with pancreatitis.
    Roquin G; Peres M; Lerolle N; Dib N; Mercat A; Croue A; Augusto JF
    Ann Pharmacother; 2010 Dec; 44(12):1998-2000. PubMed ID: 21098750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.
    Nguyen BY; Isaacs RD; Teppler H; Leavitt RY; Sklar P; Iwamoto M; Wenning LA; Miller MD; Chen J; Kemp R; Xu W; Fromtling RA; Vacca JP; Young SD; Rowley M; Lower MW; Gottesdiener KM; Hazuda DJ
    Ann N Y Acad Sci; 2011 Mar; 1222():83-9. PubMed ID: 21434946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulphasalazine-induced DRESS.
    Teo L; Tan E
    Singapore Med J; 2006 Mar; 47(3):237-9. PubMed ID: 16518561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case reports: treatment of nevirapine-associated dress syndrome with intravenous immune globulin (IVIG).
    Fields KS; Petersen MJ; Chiao E; Tristani-Firouzi P
    J Drugs Dermatol; 2005; 4(4):510-3. PubMed ID: 16004028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens].
    Kravchenko AV
    Ter Arkh; 2010; 82(11):27-32. PubMed ID: 21381345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug reaction with eosinophilia and systemic symptoms associated with raltegravir use: case report and review of the literature.
    Ripamonti D; Benatti SV; Di Filippo E; Ravasio V; Rizzi M
    AIDS; 2014 Apr; 28(7):1077-9. PubMed ID: 24685746
    [No Abstract]   [Full Text] [Related]  

  • 17. Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update.
    Tas S; Simonart T
    Dermatology; 2003; 206(4):353-6. PubMed ID: 12771485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line raltegravir. No evidence of comparative effectiveness.
    Prescrire Int; 2010 Nov; 19(110):248-50. PubMed ID: 21284354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
    Anderson MS; Kakuda TN; Hanley W; Miller J; Kost JT; Stoltz R; Wenning LA; Stone JA; Hoetelmans RM; Wagner JA; Iwamoto M
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4228-32. PubMed ID: 18838586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.